养血疏风方治疗慢性荨麻疹的临床疗观察及作用机制研究

胡传国; 王雯; 陈禧; 范灵芝; 梁俊琴

文章摘要

养血疏风方治疗慢性荨麻疹的临床疗观察及作用机制研究

Clinical observation and mechanism of Yangxue Shufeng Formula in the treatment of chronic urticaria

投稿时间：2026-09-30 修订日期：2026-09-30

DOI：

中文关键词: 养血疏风方慢性荨麻疹免疫炎症反应 Toll样受体4/髓样分化因子88/核转录因子-κB信号通路

英文关键词: Yangxue Shufeng Formula Chronic urticaria Immune inflammatory responses TLR4/MyD88/NF-κB signaling pathway

基金项目:新疆维吾尔自治区自然科学基金面上项目(No 2024D01C97)

作者	单位	邮编
胡传国^*	新疆维吾尔自治区人民医院	830001
王雯	新疆维吾尔自治区人民医院中西医协同医学诊疗中心
陈禧	新疆维吾尔自治区人民医院中西医协同医学诊疗中心
范灵芝	新疆维吾尔自治区人民医院中西医协同医学诊疗中心
梁俊琴	新疆维吾尔自治区人民医院中西医协同医学诊疗中心

摘要点击次数: 614

全文下载次数: 0

中文摘要:

目的观察养血疏风方治疗慢性荨麻疹患者的临床疗效及调控机制。方法选取新疆维吾尔自治区人民医院2025年1月至2026年6月收治的140例慢性荨麻疹患者，按照随机数字表法分为对照组和观察组，每组各70例。对对照组患者口服枸地氯雷他定片，1片/次，1次/d；观察组患者口服养血疏风方，1剂/d，早晚两次服用，两组均治疗4周。比较两组患者临床疗效，患者症状及体征评分，荨麻疹活动性评分（UAS）、皮肤病生活质量指数评分（DLQI），血清干扰素-γ（IFN-γ）、白细胞介素-2（IL-2）、白细胞介素-4（IL-4）、免疫球蛋白E（IgE）水平，Toll样受体4（TLR4）、髓样分化因子88（MyD88）、核转录因子-κB（NF-κB）mRNA水平以及不良反应发生率。结果观察组总有效率高于对照组（P<0.05）。治疗后，两组症状及体征评分，UAS评分、DLQI评分、血清IL-4、IgE、TLR4、MyD88、NF-κB mRNA水平较治疗前均降低（P<0.05），且观察组低于对照组（P<0.05）。IFN-γ、IL-2水平较治疗前均升高（P<0.05），且观察组高于对照组（P<0.05）。两组不良反应发生率比较无统计学差异（P>0.05）。结论养血疏风方治疗慢性荨麻疗效显著，其可以通过抑制TLR4/MyD88/NF-κB通路，减轻免疫炎症反应，改善慢性荨麻疹患者临床症状和生活质量。

英文摘要:

Objective To observe the clinical efficacy and regulation mechanism of the Yangxue Shufeng Formula in the treatment of patients with chronic urticaria. Methods A total of 140 patients with chronic urticaria admitted to the People''s Hospital of Xinjiang Uygur Autonomous Region from January 2025 to June 2026 were selected and divided into control group and observation group according to the random number table method, with 70 cases per group. Patients received oral desloratadine citrate tablets, 1 tablet per dose, once daily in control group. Patients in the observation group received oral Yangxue Shufeng Formula, 1 dose per day, taken in the morning and evening. Both groups were treated for 4 weeks. The clinical efficacy, symptom and sign scores, serum levels of interferon-γ (IFN-γ), interleukin-2 (IL-2), interleukin-4 (IL-4), and immunoglobulin E (IgE), urticaria activity score (UAS) , dermatology life quality index (DLQI), mRNA levels of Toll-like receptor 4 (TLR4), myeloid differentiation factor 88 (MyD88), and nuclear factor-κB (NF-κB), as well as the incidence of adverse reactions were compared between the two groups. Results There was a higher clinical total effective rate in the observation group than in the control group (P<0.05). After treatment, the symptom and sign scores, serum levels of IL-4, IgE, UAS score, DLQI score and mRNA levels of TLR4, MyD88, and NF-κB were lower than post-treatment in both groups (P<0.05), and observation group was lower than control group (P<0.05). Levels of IFN-γ and IL-2 were elevated than post?treatment in both groups (P<0.05), and observation group was higher than control group (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion Yangxue Shufeng Formula has a significant therapeutic effect on chronic urticaria. It can alleviate immune inflammatory responses and improve the clinical symptoms and quality of life of patients with chronic urticaria by inhibiting TLR4/MyD88/NF-κB pathway.

下载PDF阅读器 HTML全文

关闭